all report title image
  • Published In : Apr 2024
  • Code : CMI6864
  • Pages :172
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Size and Trends

Global geriatric medicines market is estimated to be valued at USD 1,004.71 Bn in 2024 and is expected to reach USD 1,570.18 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.

Global Geriatric Medicines Market Key Factors

To learn more about this report, request a free sample copy

The geriatric population, which is the primary consumer of medicines meant for age-related diseases, is growing rapidly worldwide. Increased geriatric population base suffering from multiple co-morbidities is the major factor boosting demand for geriatric medicines. Furthermore, growing focus of pharmaceutical companies on developing specialized prescriptions for elderly care is also supporting the growth of the geriatric medicines market. However, the presence of generic drugs may hinder the market growth during the forecast period.

Aging population and prevalence of chronic diseases

As the average human lifespan continues to increase around the world, populations are witnessing an unprecedented growth in the number of elderly people aged 65 years and above. Aging leads to increased susceptibility to various chronic health conditions that often require long-term or lifelong management. Diseases such as cardiovascular disorders, cancer, diabetes, arthritis, Alzheimer's, Parkinson's, and others are highly prevalent among the geriatric demographic. The physiological changes associated with advancing age like reduced organ function, declined immunity and ability to heal present an added challenge in treatment. Furthermore, risk of polypharmacy also rises as elderly patients tend to suffer from multiple comorbidities concurrently. This growing prevalence of chronic illnesses boosts the need for a specialized range of pharmaceutical products that are tailored to the unique medical requirements of the aged population and can help improve their quality of life. Development of such geriatric-specific medicines aimed at effective management of age-related health issues can open lucrative opportunities for drug makers in the near future. 

Market Concentration and Competitive Landscape

Global Geriatric Medicines Market Concentration By Players

To learn more about this report, request a free sample copy

Need for improved medication management

Another critical driver for the geriatric medicines market is need for improved medication management among elderly individuals. Due to factors like reduced cognitive abilities, reduced organ function and higher vulnerabilities, medication regimens for senior citizens need to be designed very carefully. Issues pertaining to medication adherence, risk of adverse drug reactions and drug-drug interactions are much more common among geriatric patients on polypharmacy schedules. Factors like vision or hearing impairments can also negatively impact their ability to follow prescriptions properly, leading to treatment failures or health complications. There is growing emphasis on developing safer, easier to administer and more effective therapeutic solutions for this patient segment. Pharmaceutical companies are increasingly focusing on new delivery mechanisms, single pill combinations, customized dosing frequencies and diagnostics to facilitate optimized treatment support for the elderly population. This helps address an important clinical challenge and presents an opportunity for enhanced medical management of older demographics through innovation in geriatric drug formulations and solutions.

Global Geriatric Medicines Market Key Takeaways From Lead Analyst

To learn more about this report, request a free sample copy

Market Challenges – High drug development costs

Global geriatric medicines market faces several challenges. As the elderly population grows globally, age-related diseases are increasing which requires extensive research and development to find new treatment options. However, drug development costs are very high and bringing a new drug to the market is difficult and risky. Older patients often have multiple health issues, so testing treatments and managing side effects becomes more complex. Regulatory guidelines for clinical trials in elderly patients are stringent to ensure safety.

Market Opportunities – Development of combination drugs tailored for individual health conditions

The growth of the elderly population worldwide presents opportunities. As life expectancies increase, the demand for medicines to treat age-related chronic diseases will rise significantly. Manufacturers are working on developing safer drugs that can be used by those with co-morbidities. There is also scope for combinations of different drugs tailored for individual health conditions. Companion diagnostics can also help improve treatment outcomes for older patients, thereby, creating lucrative opportunities for market development over the projected period.

Global Geriatric Medicines Market By Disease Indication

To learn more about this report, request a free sample copy

Insights, By Disease Indication: Aging population and high cancer incidence drives oncology segment growth

Disease Indication segment is sub-segmented into oncology, orthopedic disorders, cardiovascular disorders, respiratory disorders, neurological disorders, metabolic disorders, and others. Oncology segment is estimated to hold 25.7% share of the market in 2024. As people grow older, their immune system weakens, making them more susceptible to developing cancer. Some of the common cancers affecting the elderly include breast cancer, prostate cancer, lung cancer, and colon cancer. With rising life expectancy around the world, the number of aging individuals is projected to surge dramatically over the coming decades. This burgeoning geriatric demographic will boost demand for oncology drugs designed specifically for older cancer patients. Moreover, certain types of cancers are predominantly associated with aging such as multiple myeloma which prompts heavy reliance on geriatric oncology medications. Stringent regulatory frameworks ensure the efficacy and safety of geriatric cancer treatments, further promoting their usage.

Insights, By Form: Prevalence of chronic diseases boosts tablet segment growth

Form segment is sub-segmented into tablet, liquid, capsule, inhalers, topical, and others. Tablet segment is anticipated to hold 37.8% of the market share in 2024. Older adults are more prone to develop long-term conditions like diabetes, heart disease, arthritis due to age-related physiological changes and immune system weaknesses. Tablets offer reliable and consistent dosage along with easy portability, swallowability and storage advantages, making them the preferred delivery format for managing chronic diseases over the long-term. Their solid unitary dosage form also facilitates adherence to complex drug regimens. Moreover, tablets production involves lower costs as compared to other dosage forms like liquid, thus, providing better price margins for pharmaceutical companies to cater to the massive target market of geriatric patients with diabetes, hypertension, and other chronic illnesses.

Insights, By Route of Administration: Ease of Administration Fuel Growth of Oral Administration Route

Route of Administration segment includes is sub-segmented into oral, parenteral, and others. Oral segment is anticipated to hold 56.7% of the market share in 2024. Due to aging, people develop certain medical conditions affecting swallowing ability such as dysphagia, arthritis or Parkinson's disease. Even minor swallowing difficulties can cause serious issues like choking, aspiration or malnutrition in the elderly. This prompts higher reliance on orally administered medicines which does not need specialized delivery methods. Moreover, oral drug formulations are easier to administer, have better acceptance and ensure higher compliance. With rising prevalence of dysphagia prevalence, global geriatric medicines market is advancing user-friendly or dispersible and chewable drugs to further boost convenience of oral route of administration.

Regional Insights

Global Geriatric Medicines Market Regional Insights

To learn more about this report, request a free sample copy

North America has established itself as the dominant region in the global geriatric medicines market and is anticipated to hold 36.2% of the market share in 2024. The high per capita healthcare expenditure in countries like U.S. and demand for innovative drugs to treat age-related chronic conditions have propelled the regional market growth. The U.S. alone accounts for over 65% of the North American market due to well-developed pharmaceutical industry and presence of major international drug makers in the region. In recent years, increasing preference for generic drugs to control escalating healthcare costs has emerged as a key trend in the regional market.

The Asia Pacific region is considered the fastest growing market for geriatric medicines driven by rapidly growing geriatric population, improving access to healthcare facilities and rising healthcare expenditure in emerging economies. Countries like China and India provide immense growth opportunities, owing to their huge geriatric demographic base and rising focus on quality healthcare by local governments. Several international drug manufacturers are shifting their manufacturing facilities to Asia in order to cater to regional demand in a cost-effective manner and benefit from policy incentives offered by governments. This has made APAC an important hub for generic drugs production. However, lack of comprehensive public insurance coverage in many South-East Asian countries remains a challenge for market expansion.

Market Report Scope

Global Geriatric Medicines Market Report Coverage

Report Coverage Details
Base Year: 2023 Market Size in 2024: US$ 1,004.71 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 6.6% 2031 Value Projection: US$ 1,570.18 Bn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Disease Indication: Oncology, Orthopedic Disorders, Cardiovascular Disorders, Respiratory Disorders, Neurological Disorders, Metabolic Disorders, Others
  • By Form: Tablet, Liquid, Capsule, Inhalers, Topical, Others
  • By Route of Administration: Oral, Parenteral (Intravenous, Intramuscular, Subcutaneous ), Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, Cadila Pharmaceuticals

Growth Drivers:
  • Aging population and prevalence of chronic diseases
  • Need for improved medication management 
Restraints & Challenges:
  • High drug development costs
  • Stringent Regulations for Drug Approval

Key Developments

  • In May 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in people aged 60 and older. ABRYSVO is an unadjuvanted vaccine made up of two preF proteins chosen to optimize protection against RSV A and B strains, and it has been shown to be both safe and efficacious.
  • In May 2023, Otsuka Pharmaceutical, Co. Ltd., a pharmaceutical company and Lundbeck LLC, a pharmaceutical company, announced that the U.S. FDA had approved the supplemental New Drug Application (sNDA) of REXULTI (brexpiprazole) for use in the treatment of agitation associated with dementia due to Alzheimer’s disease
  • In March 2023, The Penn Medicine Princeton Cancer Center received a USD 2.5 million grant from the Bristol Myers Squibb Foundation to fund an innovative program to ensure holistic, patient-centered care for older adults with cancer. The new Geriatric Oncology Program will transform cancer treatment and supportive care for older adults by expanding research opportunities, enhancing professionals’ expertise in geriatrics, and increasing outreach to seniors in the central New Jersey community.
  • In January 2023, Eisai Co., Ltd., a pharmaceutical company, and Biogen Inc., a multinational biotechnology company, announced that the U.S. FDA has approved lecanemab-irmb 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ("protofibril") and insoluble forms of amyloid beta (Aβ) for the treatment of Alzheimer's disease (AD).
  • *Definition: Geriatric Medicines Market refers to the market for pharmaceutical drugs that are specifically designed, developed and tested for use in the elderly patient population aged 65 years and above. These medicines aim to prevent, treat or manage aging-related chronic conditions like cardiovascular diseases, cancer, diabetes, arthritis, neurological disorders and dementia. These also aim to improve quality of life by reducing the effects of aging on physiological functioning. Geriatric Medicines Market plays a crucial role in helping senior citizens live independently and healthy lives.

Market Segmentation

  • Disease Indication Insights (Revenue, USD Bn, 2019 - 2031)
    • Oncology
    • Orthopedic Disorders
    • Cardiovascular Disorders
    • Respiratory Disorders
    • Neurological Disorders
    • Metabolic Disorders
    • Others
  •  Form Insights (Revenue, USD Bn, 2019 - 2031)
    • Tablet
    • Liquid
    • Capsule
    • Inhalers
    • Topical
    • Others
  •  Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
    • Oral
    • Parenteral
      • Intravenous
      • Intramuscular
      • Subcutaneous 
    • Others
  •  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Janssen Pharmaceuticals
    • Sun Pharmaceutical Industries Ltd.
    • AbbVie Inc.
    • Boehringer Ingelheim
    • Eli Lilly and Company
    • Bristol Myers Squibb
    • Daiichi Sankyo Company, Limited
    • Bausch Health Companies
    • Mallinckrodt Pharmaceuticals
    • Endo Pharmaceuticals
    • Eisai Co., Ltd.
    • Ferring Pharmaceuticals
    • UCB
    • Evoke Pharma
    • Cadila Pharmaceuticals

Frequently Asked Questions

The CAGR of global geriatric medicines market is projected to be 6.6% from 2024 to 2031.

Aging population and prevalence of chronic diseases and need for improved medication management are the major factor driving the growth of global geriatric medicines market.

High drug development costs and stringent regulations for drug approval are the major factor hampering the growth of global geriatric medicines market.

In terms of disease indication, oncology segment is  estimated to dominate the market in 2024.

North America is expected to lead the global geriatric medicines market

Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, Cadila Pharmaceuticals are the major players.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Reliability and Reputation


Reliability and Reputation


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo